SCHEMBL643461

SCHEMBL643461

CCCC(C(=O)O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.53
CYP2D6 P10635 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
KCNQ2 O43526 1/20 0.48
LMNA P02545 3/20 0.47
HSD17B10 Q99714 1/20 0.47
SRC P12931 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
AOC3 Q16853 1/20 0.46
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.45
TBXAS1 P24557 1/20 0.44
MME P08473 1/20 0.44
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19228532 1.00 CYP2C19 (0.53) CYP2C19CYP2D6CYP1A2CYP3A4CYP2C9
Water SCHEMBL27452260 0.98 CYP2C19 (0.52) CYP2C19CYP2D6CYP1A2CYP3A4CYP2C9
Hydrochloric Acid SCHEMBL16401889 0.98 CYP2C19 (0.52) CYP2C19CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL455432 0.88 POLB (0.53) CYP2C19LMNAHSD17B10SMN1; SMN2MAPK1
SCHEMBL10547787 0.87 CYP2C19 (0.46) CYP2C19CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL30371912 0.87 CYP2C19 (0.61) CYP2C19CYP2D6LMNASRCSMN1; SMN2
SCHEMBL4444443 0.86 TBXAS1 (0.51) CYP2C19LMNAPOLBTBXAS1MME
SCHEMBL1911433 0.86 TBXAS1 (0.51) CYP2C19LMNAPOLBTBXAS1MME
SCHEMBL27541113 0.86 POLB (0.51) CYP2C19LMNAHSD17B10SMN1; SMN2MAPK1
SCHEMBL6728896 0.86 CYP2C19 (0.49) CYP2C19CYP2D6CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119507208-A Preparation method of soft hydrophobic fabric 广东群豪服饰有限公司 2025-02-25 CN claimed
CN-118958076-A Artificial lawn and preparation method thereof 江苏共创人造草坪股份有限公司 2024-11-15 CN claimed
US-20240269066-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA PRECVISION BIOTECHNOLOGIES LTD. (CN) 2024-08-15 US claimed
CN-116060124-B Oil-soluble organic metal salt composition and preparation method and application thereof 中国石油化工股份有限公司 2024-06-28 CN claimed
CN-117925426-A Rhodotorula mucilaginosa (Rhodotorula mucilaginosa) strain 147 and application, product and method thereof 宁夏农产品质量标准与检测技术研究所(宁夏农产品质量监测中心) 2024-04-26 CN claimed
EP-4353264-A1 USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME Precvision Biotechnologies Ltd. (CN) 2024-04-17 EP claimed
CN-114315636-B Synthesis method of 1-propyl- [4- (4' -butylphenylazo) ] azobenzene 烟台丰鲁精细化工有限责任公司 2024-02-27 CN claimed
CN-117004344-A Carboxyl styrene-butadiene latex for lithium battery cathode and preparation method thereof 淄博奥固特科技有限公司 2023-11-07 CN claimed
CN-116165095-A Method and equipment for rapidly detecting solid content of carboxyl styrene-butadiene latex 河北昊泽化工有限公司 2023-05-26 CN claimed
CN-116060124-A Oil-soluble organic metal salt composition and preparation method and application thereof 中国石油化工股份有限公司 2023-05-05 CN claimed
US-20050267168-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2005-12-01 US claimed
CN-1200703-C Use of pentanoate derivant ONO PHARMACEUTICAL CO (JP) 2005-05-11 CN claimed
US-20030096802-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2003-05-22 US claimed
CN-1322524-A Use of pentanoate derivant ONO PHARMACEUTICAL CO (JP) 2001-11-21 CN claimed
US-6201021-B1 TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES ONO PHARMACEUTICAL CO., LTD. (JP) 2001-03-13 US claimed
EP-0632008-B1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO (JP) 1998-02-04 EP claimed
CN-1100408-A Pentanoic acid derivatives ONO PHARMACEUTICAL CO (JP) 1995-03-22 CN claimed
EP-0632008-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1995-01-04 EP claimed
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 US claimed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267168-A1 Pentanoic acid derivatives FFAR3, FFAR1, HCAR3 CYP2C19 1586/4885CYP2D6 1818/4885CYP1A2 3287/4885
US-20030096802-A1 Pentanoic acid derivatives FFAR3, FPR1, FPR3 CYP2C19 3633/4885CYP2D6 1720/4885CYP1A2 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.